Source: Eur Respir J 2015; 45: 76-86
Disease area: Airway diseases, Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Clark Tristan W., Medina Marie-Jo, Batham Sally, Curran Martin D., Parmar Surendra, Nicholson Karl G.. C-reactive protein level and microbial aetiology in patients hospitalised with acute exacerbation of COPD. Eur Respir J 2015; 45: 76-86

Member's Comments

No comment yet.

Related content which might interest you: The importance of C-reactive protein in patients with acute exacerbation of severe COPD Source: International Congress 2019 – Airway disease-associated exacerbations Year: 2019 Thromboprophylaxis and the relationship between C-reactive protein and plasma fibrinogen in patients with acute exacerbations of COPD Source: Eur Respir J 2007; 30: Suppl. 51, 555s Year: 2007 Are C-reactive protein levels associated with bacteria in COPD exacerbations? Source: Eur Respir J 2015; 45: 1514-1515 Year: 2015 Are C-reactive protein levels associated with bacteria in COPD exacerbations? Source: Eur Respir J 2015; 45: 1515-1516 Year: 2015 C-reactive protein usefulness in diagnosis and follow-up of COPD infectious exacerbations Source: Annual Congress 2007 - Different aspects of COPD exacerbations Year: 2007 Quantification of severity of the acute exacerbation in hospitalized COPD patients Source: Eur Respir J 2003; 22: Suppl. 45, 559s Year: 2003 Serum SP-A and SP-D levels in patients admitted to the hospital with acute COPD exacerbation Source: International Congress 2016 – Inflammatory biomarkers in airway diseases Year: 2016 Relationship between CRP levels and the severity of COPD acute exacerbations among group D COPD patients. Source: Virtual Congress 2020 – COPD phenotypes Year: 2020 Serum interleukin-6 levels correlate with malnutrition in patients with acute exacerbation of COPD Source: Annual Congress 2009 - Organisation of care for individuals with chronic respiratory disease Year: 2009 C-reactive protein levels and clinically important predictive outcomes in stable COPD patients Source: Eur Respir J 2006; 27: 902-907 Year: 2006 Clinical value of C-reactive protein in severe acute exacerbations of COPD Source: Annual Congress 2005 - COPD - acute exacerbations Year: 2005 Influence of bronchiectasis in patients hospitalized due to acute exacerbation of COPD. Source: International Congress 2017 – Towards personalised medicine in COPD: biological and clinical phenotypes Year: 2017 Performance of rapid, bedside whole blood C-reactive protein (CRP) test as a diagnostic test for bacterial infection and pneumonia in patients with acute exacerbation of chronic obstructive pulmonary disease (AE COPD) Source: Eur Respir J 2007; 30: Suppl. 51, 557s Year: 2007 The role of viral infections in patients admitted with acute exacerbation of COPD Source: Eur Respir J 2004; 24: Suppl. 48, 408s Year: 2004 Combined serum eosinophil count and procalcitonin level as a marker of bacterial infection in acute exacerbation of chronic obstructive pulmonary disease Source: International Congress 2016 – Systemic biomarkers Year: 2016 Copeptin – a marker for differential diagnosis between acute exacerbation of COPD and heart failure in patients with acute dyspnea Source: Virtual Congress 2021 – Biomarkers for the management of bronchial obstructive diseases Year: 2021 Procalcitonin versus C-reactive protein in the management of severe acute exacerbations of COPD Source: Annual Congress 2010 - Aetiology and outcomes of infective exacerbations of COPD Year: 2010 The validity of the EQ5D5L in patients hospitalized an acute exacerbation of COPD Source: International Congress 2017 – Latest insights into chronic care Year: 2017 C-reactive protein (CRP) as a marker of disease severity in community acquired pneumonia patients with sepsis Source: Annual Congress 2012 - Infections and sepsis in the ICU Year: 2012 Is CRP really valid acute-phase inflammation reactant in all patients with sputum bacterial positive culture in acute exacerbation of COPD? Source: Annual Congress 2010 - COPD: systemic inflammation and comorbidities Year: 2010